Interferon Beta Drugs Market, By Product Type (Interferon Beta-1A, Interferon Beta-1B, Peginterferon Beta-1A), By Route Of Administration (IntramuscularIntramuscular, Subcutaneous, Intravenous), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Published In : Sep 2023

Code : CMI4250

Pages :169

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Interferon Beta Drugs Market: Key Developments

In June 2022, Astellas Pharma Inc., a Japan-based multinational pharmaceutical company, and Sutro Biopharma, Inc., a public biotechnology company, entered a global strategic partnership and licensing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs).
In November 2022, Nektar, a global biopharmaceutical company focused on the discovery and development of novel therapies that selectively modulate the immune system to treat autoimmune disorders, announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for Immunotherapy of Cancer (SITC), an organization specifically dedicated to improving cancer patient outcomes, annual meeting. NKTR-288 is a novel polyethylene glycol (PEG)-conjugate of interferon gamma (IFN-γ), designed to modify the binding of IFN-γ to its substrates and optimize the duration of IFN-γ signaling. The presentation showed the sustained pharmacological properties of NKTR-288 relative to native cytokines, including durable exposure and induction of the well-characterized interferon gamma response.
On December 11, 2022, Takeda Pharmaceutical Company Limited, a Japan-based multinational pharmaceutical company, announced that their investigational new drug (IND) known as modakafusp has shown early potential in combating multiple myeloma, a form of bone marrow cancer. Modakafusp is a fusion protein that targets interferon (a pro-inflammatory hormone that is also used for treating viral infections and other cancers) to cells that have CD38, a surface marker present on myeloma cells and a variety of immune cells.